DUBLIN--(BUSINESS WIRE)--Sep 11, 2018--The "Fabry Disease - Market Insights, Epidemiology and Market Forecast - 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

The therapeutic market of Fabry disease in 7MM is expected to reach USD 2.1 Billion in 2025.Anderson-Fabry Disease - Market Insights, Epidemiology & Market Forecast-2025 provides an overview of the Anderson-Fabry Disease, epidemiology and market trend of the Anderson-Fabry Disease for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Anderson-Fabry Disease from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Anderson-Fabry Disease till 2025. It also covers market drivers, market barriers and unmet medical need.

Our report provides the subtype specific prevalent population i.e. Classic Fabry Disease and Later-onset Fabry disease. According to research, the prevalent population of Anderson-Fabry Disease is expected to reach up to XXX cases by the end of 2025 at a CAGR of 1.3% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

Fabry Disease market has experienced a continuous growth due to approved therapies such as Fabrazyme (agalsidase beta) from Sanofi Genzyme and Replagal (ERT based therapy) from Shire. Sanofi Genzyme is currently dominating the Fabry market with its lead product Fabrazyme.

United States contributes the major share of Fabry disease market as compared to EU5 countries and Japan.

Key Topics Covered:

1. Report Introduction

2. Disease Background and Overview

3. Introduction

4. Epidemiology and Patient Population

5. Treatment Practices

6. Treatment Goals

7. Treatment Algorithm

8. Marketed Drugs List

9. Marketed Drugs

Companies Mentioned

Amicus Therapeutics, Inc.Shire Plc.Sanofi-AventisProtalix BiotherapeuticsFor more information about this drug pipelines report visit https://www.researchandmarkets.com/research/38tbmw/global_fabry?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005388/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/11/2018 07:00 AM/DISC: 09/11/2018 07:01 AM